# US 2019/0167805 A1 · Immunoconjugates with an Intracellularly-Cleavable Linkage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167805 A1
- Document ID: US20190167805A1
- Status: Published application
- Kind: A1
- Application number: 16/276,173
- Filed: 2019-02-14
- Published: 2019-06-06
- Earliest claimed: 2009-02-13
- Assignees: Immunomedics, Inc.
- Applicants: Immunomedics, Inc.
- Inventors: Serengulam V. Govindan; Sung-Ju Moon; David M. Goldenberg
- Web page: https://patentgrep.com/patent/US20190167805A1

## CPC

- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6841: {the antibody targeting a RNA virus}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6853: {Carcino-embryonic antigens}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6857: {the tumour determinant being from lung cancer cell}
- A61K 47/6859: {the tumour determinant being from liver or pancreas cancer cell}
- A61K 47/6861: {the tumour determinant being from kidney or bladder cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07K 16/18: against material from animals or humans
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3076: {against structure-related tumour-associated moieties}
- C07K 16/3092: {against tumour-associated mucins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/53: Hinge
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

## Claims

### Claim 1

A method for treating an autoimmune disease comprising administering to an individual with an autoimmune disease an immunoconjugate having a structural formula MAb-linker-SN-38, wherein the linker-SN-38 has a structure represented by:
wherein n is between 1 and 30; AA is an L-amino acid residue selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; and MAb is an IgG antibody or antigen-binding antibody fragment that binds to a B-cell antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein n is between 1 and 12.

### Claim 3 (depends on 1)

The method of claim 1, wherein n is between 6 and 12.

### Claim 4 (depends on 1)

The method of claim 1, wherein n is 8.

### Claim 5 (depends on 1)

The method of claim 1, wherein AA is a lysine residue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the MAb is a murine, chimeric, humanized, or human monoclonal antibody or antigen binding fragment thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein said fragment is selected from the group consisting of Fab, Fab′, F(ab)2, F(ab′)2, and scFv.

### Claim 8 (depends on 6)

The method of claim 6, wherein the MAb has constant domains and a hinge domain of a human IgG1 or a human IgG4 antibody.

### Claim 9 (depends on 6)

The method of claim 6, wherein the MAb has constant domains and a hinge domain of a human IgG4 antibody, wherein serine 228 of the hinge is replaced with proline.

### Claim 10 (depends on 1)

The method of claim 1, wherein the B-cell antigen is selected from the group consisting of CD19, CD20, CD22, CD74 and HLA-DR.

### Claim 11 (depends on 1)

The method of claim 1, wherein the antibody is selected from the group consisting of hA19, hA20 (veltuzumab), hLL1 (milatuzumab), hLL2 (epratuzumab), hL243 and rituximab.

### Claim 12 (depends on 1)

The method of claim 1, wherein the immunoconjugate is made by reacting a maleimide moiety of the linker-SN38 with a reduced sulfhydryl of the MAb.

### Claim 13 (depends on 1)

The method of claim 1, wherein the immunoconjugate is made by:
a) generating one or more thiols on the antibody by reacting at least one lysine residue on the antibody with a thiolating reagent; and
b) reacting a maleimide moiety of the linker-SN38 with the thiol group on the lysine residue.

### Claim 14 (depends on 1)

The method of claim 1, wherein said MAb is attached to between 1 and 12 copies of the linker-SN38.

### Claim 15 (depends on 1)

The method of claim 1, wherein said MAb is attached to between 6 and 8 copies of linker-SN38.

### Claim 16 (depends on 1)

The method of claim 1, wherein said MAb is attached to between 1 and 5 copies of linker-SN38.

### Claim 17

A method for treating an autoimmune disease comprising administering to an individual with an autoimmune disease an immunoconjugate having a structural formula MAb-linker-SN-38, wherein the linker-SN-38 has a structure represented by:
wherein n is between 1 and 30; AA is an L-amino acid residue selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; R is a thiol-reactive moiety; and MAb is an IgG antibody or antigen-binding antibody fragment that binds to a B-cell antigen.

### Claim 18 (depends on 17)

The method of claim 17, wherein the thiol-reactive moiety is selected from the group comprised of maleimide, vinylsulfone, bromoacetamide and iodoacetamide.

### Claim 19 (depends on 18)

The method of claim 18, wherein the maleimide moiety is a trans 4-maleimidomethylcyclohexyl moiety.

### Claim 20 (depends on 19)

The method of claim 19, wherein the immunoconjugate is made by reacting the thiol-reactive moiety of the linker-SN38 with a reduced sulfhydryl of the MAb.

### Claim 21 (depends on 20)

The method of claim 20, wherein the immunoconjugate is made by:
a) generating one or more thiols on the antibody by reacting at least one lysine residue on the antibody with a thiolating reagent; and
b) reacting the thiol-reactive moiety of the linker-SN38 with the thiol group on the lysine residue.

### Claim 22 (depends on 17)

The method of claim 17, wherein the B-cell antigen is selected from the group consisting of CD19, CD20, CD22, CD74 and HLA-DR.

### Claim 23 (depends on 17)

The method of claim 17, wherein the antibody is selected from the group consisting of hA19, hA20 (veltuzumab), hLL1 (milatuzumab), hLL2 (epratuzumab), hL243 and rituximab.
